A general protein disulfide isomerase inhibitor can protect against reductions in ATP levels in an in vitro Huntington disease model [12], supporting the notion that PDIA3 might inhibit mitochondrial bioenergetic function. Here, PDIA3 is linked to juvenile Huntington disease.